This article has been updated with current information from Veracyte.
NEW YORK (GenomeWeb) – Investment bank Leerink has reinitiated coverage of Veracyte with an Outperform rating and a price target of $12 on the firm's stock.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.